AgingResearch.NewsJoin free
The Lancet Oncology

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

By Sara Alsterlind Hurvitz, Fabrice André, Zefei Jiang, Show 16 more authorsDennis J. Slamon
Trial in peopleInterventions
Paper

The paper

Sara Alsterlind Hurvitz, Fabrice André, Zefei Jiang, Show 16 more authorsDennis J. Slamon

University of California, Los Angeles

The Lancet Oncology, 16 Jun 2015

doi.org/10.1016/s1470-2045(15)00051-0PubMed 26092818

More in Interventions